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Abstract 
Background: Von Hippel–Lindau (VHL) syndrome is a dominantly inherited multisystem cancer syndrome caused by 
a heterozygous mutation in the VHL tumor suppressor gene. Previous studies suggested that similar populations of 
Caucasian and Japanese patients have similar genotype or phenotype characteristics. In this comprehensive study of 
East Asian patients, we investigated the genetic and clinical characteristics of patients with VHL syndrome.
Methods: To create a registry of clinical characteristics and mutations reported in East Asian patients with VHL 
syndrome, we conducted a comprehensive review of English language and non‑English language articles identi‑
fied through a literature search. Publications in Japanese or Chinese language were read by native speakers of the 
language, who then performed the data extraction.
Results: Of 237 East Asian patients with VHL syndrome, 154 unique kindreds were identified for analysis. Analyzed 
by kindred, missense mutations were the most common (40.9%, 63/154), followed by large/complete deletions 
(32.5%, 50/154) and nonsense mutations (11.7%, 18/154). Compared with a previously reported study of both East 
Asian and non‑East Asian patients, we found several key differences. First, missense and frameshift mutations in the 
VHL gene occurred less commonly in our population of East Asian patients (40.9% vs. 52.0%; P = 0.012 and 8.4% vs. 
13.0%; P < 0.001, respectively). Second, large/complete deletions were more common in our population of East Asian 
patients (32.5% vs. 10.5%; P < 0.001). Third, phenotypically, we observed that, in our population of East Asian patients 
with VHL syndrome, the incidence of retinal capillary hemangioblastoma was lower, whereas the incidence of renal 
cell carcinoma was higher.
Conclusions: Evidence suggests that the genotypic and phenotypic characteristics of East Asian patients with VHL 
syndrome differ from other populations. This should be considered when making screening recommendations for 
VHL syndrome in Asia.
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Background
Von Hippel–Lindau (VHL) syndrome is an inherited 
multisystem cancer syndrome with an estimated inci-
dence of 1 in 36,000 live births [1]. Those affected are 
predisposed to a spectrum of benign and malignant 
tumors of the central nervous system, retina, kidney, 
adrenal gland, pancreas, reproductive adnexal organ, and 
inner ear [2, 3].
Von Hippel–Lindau syndrome is transmitted in an 
autosomal dominant fashion and has a penetrance 
reported to exceed 90% by 60 years of age [4]. It is caused 
by germline mutations in the VHL tumor suppressor 
gene, located on the short arm of chromosome 3. The 
gene consists of 3 exons and encodes 2 protein products: 
a full-length 30-kDa form (p30) composed of 213 amino 
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acids and a 19-kDa form (p19). The VHL protein (pVHL) 
is the substrate-binding subunit of an E3 ubiquitin ligase 
complex and has an alpha domain and a beta domain 
[5]. Through its beta domain, pVHL binds directly to 
hypoxia-inducible factor (HIF) [6] and targets the HIF 
alpha subunit for oxygen-dependent proteolysis [7].
Interfamilial differences in pheochromocytoma (PCC) 
susceptibility have been recognized, and a clinical classi-
fication of VHL syndrome was created based on the risk 
of developing PCC: VHL patients with type 1 disease are 
at low risk, whereas those with type 2 disease are at high 
risk [8, 9]. The cancer phenotypes of type 2 disease have 
been further subdivided based on the likelihood of devel-
oping renal cell carcinoma (RCC): type 2A and type 2B 
have a low and high likelihood, respectively; patients with 
type 2C disease develop PCCs only, without developing 
RCCs or hemangioblastomas [2]. Over 900 mutations of 
the VHL gene have been described [10]. The mutations 
accounting for type 1 disease include missense mutations 
(43%), frameshift mutations (17%), nonsense mutations 
(13%), partial/complete deletions (10%), splice (9%), and 
in-frame deletion/insertions (8%) [11]. Most mutations 
associated with type 2 disease are missense mutations [9, 
11].
In the present study, we consolidated published data 
on genetic and clinical information about VHL syndrome 
in Asia to further understand the spectrum of VHL syn-




Patients were identified through the clinical cancer 
genetics service in the National Cancer Centre Singa-
pore. Before informed consent was provided to obtain 
blood samples for genetic testing, patients were provided 
genetic counseling by specialized clinical cancer geneti-
cists. Patients and their families with confirmed VHL 
mutations were selected for the study and registered 
in a database. Institutional review board approval was 
obtained for this study.
Literature search strategy
On June 15, 2012, we performed a systematic search on 
PubMed using the following search strategy: “(von Hip-
pel Lindau Disease OR Familial Cerebello-Retinal Angio-
matosis OR Angiomatoses, Familial Cerebello-Retinal 
OR Angiomatosis, Familial Cerebello-Retinal OR Cere-
bello-Retinal Angiomatoses, Familial OR Cerebello-Reti-
nal Angiomatosis, Familial OR Familial Cerebello Retinal 
Angiomatosis OR Familial Cerebello-Retinal Angioma-
toses OR von Hippel–Lindau Syndrome OR Syndrome, 
von Hippel–Lindau OR von Hippel Lindau Syndrome 
OR Lindau Disease OR Lindau’s Disease OR Lindau’s 
Diseases OR Lindaus Disease OR Cerebelloretinal Angio-
matosis, Familial OR Angiomatoses, Familial Cerebello-
retinal OR Angiomatosis, Familial Cerebelloretinal OR 
Cerebelloretinal Angiomatoses, Familial OR Familial 
Cerebelloretinal Angiomatoses OR Familial Cerebelloret-
inal Angiomatosis OR Hippel–Lindau Disease OR Hippel 
Lindau Disease) AND (China OR Hong Kong OR Chi-
nese OR Japan OR Japanese OR Korea OR Korean OR 
Taiwan OR Republic of China OR Taiwanese).”
All available articles were reviewed and included for 
analysis if both genotype and phenotype information 
were reported. Articles in the Chinese and Japanese lan-
guages were reviewed by native speakers. All data were 
input into a standardized template. We extracted the fol-
lowing data: (i) genetic information—sequence variation 
at the DNA and protein levels [12], and type of variation 
(e.g., missense); (ii) clinical information—diagnosis of 
central nervous system hemangioblastoma, retinal capil-
lary hemangioblastoma (RCH), PCC, pancreatic cyst or 
tumor, renal cyst or tumor, endolymphatic sac tumor, or 
papillary cystadenoma of the epididymis or broad liga-
ment; (iii) patient demographics—age at first diagnosis, 
sex, nationality, race, and familial or sporadic inheritance; 
and (iv) article publication data—journal, year of publica-
tion, and authors.
The open source program Mutalyzer was used to check 
the protein consequences of mutations [13]. To avoid 
duplication of data, if the same sequence variation was 
reported at the DNA level, we compared patient national-
ity, sex, age of first diagnosis, and disease manifestations 
to determine the likelihood of duplicate data. The entire 
dataset is included in the Additional file 1: Table S1.
Statistical analysis
The data from all VHL families were analyzed (Addi-
tional file  1: Table S1). SPSS 16.0 software (SPSS Inc., 
Chicago, IL, USA) was used for statistical analysis. Clini-
cal characteristics were compared with the Chi square 




The described search strategy of VHL syndrome in an 
East Asian population identified 347 articles. Of the total 
of 237 East Asian VHL patients, 154 kindreds were iden-
tified for analysis based on available genotype and pheno-
type information.
Local patient selection
Ten affected individuals from 7 families in Singapore 
were identified.
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Analysis of mutations
In our study of East Asian patients, we calculated the fre-
quency of each mutation and then compared this with the 
dataset reported by Nordstrom-O’Brien et al. [11], which 
included both Asian and non-Asian patients. Analyzed 
by similarity, the most common mutation was missense 
(63/154, 40.9%), followed by large/complete deletions 
(50/154, 32.5%) and nonsense mutation (18/154, 11.7%). 
Frameshift, splice, and in-frame deletions/insertions 
occurred in 8.4% (13 of 154), 4.5% (7 of 154), and 1.3% (2 
of 154) of patients, respectively (Table 1).
In our study, missense mutations in the VHL gene were 
the most common; this was also the most common class 
of  mutation reported by Nordstrom-O’Brien et  al. [11]. 
Missense mutations were more common in the series 
reported by Nordstrom-O’Brien et  al. [11], which com-
prised both East Asian and non-East Asian patients, than 
in our cohort (52.0% vs. 40.9%, P  =  0.012). Frameshift 
mutations were more common in the series reported 
by Nordstrom-O’Brien et al. [11], as compared with our 
series of East Asian patients (13.0% vs. 8.4%, P < 0.001). 
In contrast, large/complete deletions were more common 
in our series (32.5% vs. 10.5%, P < 0.001).
We analyzed the distribution of exon deletions 
(Table 2) and compared this with the data collected by 
McNeill et al. [14] via the VHL Registry at Birmingham 
Women’s Hospital and the Department of Medical and 
Molecular Genetics, University of Birmingham, United 
Kingdom. No difference was found in the distribution 
of exon deletions. The most common mutation was a 
large deletion of exons 1, 2, and 3. Of those patients 
who had deletion of a single exon (22 of 50 similar 
mutations), exon 3 was the most commonly involved 
exon. No significant difference was observed in the 
distribution of exon deletions or in the risk of develop-
ing central nervous system hemangioblastoma, RCC, 
or RCH, irrespective of whether there was complete 
deletion of the VHL gene or incomplete deletion of the 
VHL gene (Table 3).
The most common single amino acid mutation was 
c.499 C>T (p.Arg167Trp), which was present in 4.5% (7 
of 154) of patients (Fig. 1).
We found that 89.5% (17 of 19) of East Asian patients 
who developed PCC had an underlying missense muta-
tion. The most frequently mutated residues in patients 
with PCC were Arg167 (36.8%, 7 of 19) and Arg161 
(15.8%, 3 of 19),
Phenotype
In our study of East Asian patients, we observed that the 
incidence of RCH was 27.9% (43 of 154). RCH was pre-
sent in 38.1% (24 of 63) East Asian VHL kindreds with 
missense mutations, 2.5% (3 of 24) with complete exon 
deletions, and 19.2% (5 of 26) with exon deletions.
The overall frequency of RCC in this cohort was 57.8% 
(89 of 154). The frequency of RCC was 55.6% (10 of 18) in 
the families with nonsense mutations compared with 63.5% 
(40 of 63) in those with missense mutations (P =  0.541). 
A smaller proportion of families with frameshift muta-
tions—46.2% (6 of 13 families)—developed RCC.
Discussion
This study consolidated all published reports about 
VHL syndrome in East Asian patients for whom both 
genetic and clinical information were available, with 
which we could better understand the spectrum of VHL 
syndrome.
Table 1 Summary of the distribution of genetic mutations 
in  the von Hippel–Lindau (VHL) gene between  East Asian 
and Western patient cohorts
Type of VHL mutation East Asian patients Western 
patients [11] (%)
Missense 40.9% (63 of 154) 52.1
Exon 1 16.8% (26 of 154) 21.4
Exon 2 5.8% (9 of 154) 8.8
Exon 3 18.2% (28 of 154) 21.9
Frameshift 8.4% (13 of 154) 13.3
Exon 1 3.9% (6 of 154) 5.8
Exon 2 2.6% (4 of 154) 3.2
Exon 3 2.0% (3 of 154) 4.3
Nonsense 11.7% (18 of 154) 11.3
Exon 1 6.5% (10 of 154) 4.6
Exon 2 0% (0 of 154) 1.3
Exon 3 5.2% (8 of 154) 5.4
Large/complete deletion 32.5% (50 of 154) 10.8
Exon 1 5.2% (8 of 154) 1.1
Exon 2 3.2% (5 of 154) 0.4
Exon 3 5.8% (9 of 154) 0.3
Exons 1 and 2 0.6% (1 of 154) 0.3
Exons 1 and 3 0 (0 of 154) 0.2
Exons 2 and 3 1.3% (2 of 154) 0.4
Exons 1, 2 and 3 15.6% (24 of 154) 0.4
Exon not identified 0.6% (1 of 154) 6.8
Complete del 0% (0 of 154) 0.9
Splice 4.5% (7 of 154) 6.8
Exon 1 2.6% (4 of 154) 0.1
Exon 2 1.3% (2 of 154) 1.4
Exon 3 0.6% (1 of 154) 1.3
Location unknown 0% 4.0
In-frame deletion/insertion 1.3% (2 of 154) 5.6
Exon 1 1.3% (2 of 154) 5.1
Exon 2 0% (0 of 154) 0.2
Exon 3 0% (0 of 154) 0.3
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PCCs associated with VHL syndrome
We found that 89.5% (17 of 19) of East Asian kindreds 
who developed PCC had an underlying missense muta-
tion. This is consistent with the results in earlier studies 
that identified a missense mutation in the VHL gene in 
83.5% to 96% of VHL patients who developed PCC [9, 
11, 15]. The remaining 10.5% of patients in our study 
who developed PCC had a frameshift mutation. Again, 
these results are similar to those reported by Nordstrom-
O’Brien et al. [11], who found that 7% of VHL type 2 fam-
ilies had frameshift mutations.
The most frequently mutated residues in this East 
Asian cohort were Arg167 (36.8%) and Arg161 (15.8%), 
which are both surface missense mutations. The Arg167 
residue has been reported by Stebbins et  al. [5] to have 
a structural role in stabilizing the H1 helix and the α-β 
domain interface. Forman et al. [16] used bioinformatics 
tools to determine that mutations at residues 161, 164, 
and 166 are at conserved sites with elongin C interactions 
and thus interfere with the elongin C interface. In our 
cohort, 3 of 4 matched patients who had the mutation 
Arg161Gln developed PCC at ages 10, 18, and 33 years. 
None of the 4 matched patients with a truncating muta-
tion at Arg161 had PCC, which is consistent with our 
findings that most patients who develop PCC carry a 
missense mutation.
In our series, 12.3% of patients had type 2 VHL syn-
drome. In 1995, the Clinical Research Group for VHL in 
Japan reviewed data from Japan and reported that 9% of 
the evaluated patients had type 2 VHL syndrome [9]. A 
more recent nationwide epidemiologic survey of VHL 
syndrome in Japan reported a higher incidence of 15.1% 
for PCC [17]. Although improved screening may account 
for increased detection of PCC, another possibility for 
the increased incidence is age-dependent penetrance. 
The mean age at diagnosis of the first manifestation of 
VHL syndrome is between 24.7 and 26.3  years [4, 18], 
but almost complete penetrance is observed only by age 
60 [1]. Thus, in a given population, some of the clinical 
manifestations that would develop over a lifetime may 
not have manifested yet.
RCHs associated with VHL syndrome
The overall frequency of RCH in this East Asian cohort 
was 27.9% (43 of 154). In the literature, there is much 
variability in the reported frequency of RCH. Ong et al. 
[18] and Maher et al. [4] found the frequency of RCH to 
be 73% and 59%, respectively (Table 4). In a large cohort 
enrolled between 1988 and 2005 at the National Cancer 
Table 2 Comparison of  distribution of  exon deletions in  the VHL gene between  East Asian and  the cohort registered 
in Birmingham, United Kingdom
All values are presented as the number of cases followed by the percentage in parentheses
The data of the cohort registered in Birmingham, United Kingdom was reported by McNeill et al. [14]
Deletion East Asian cohort McNeill et al. [14] P value
Exon 1 AND (Exon 1 and FANCD2) 8 (16%) 8 (12.3%) 0.597
Exon 1 and 2 1 (2%) 4 (6.2%) 0.386
Exon 2 5 (10%) 12 (18.5%) 0.209
Exon 2 and 3 2 (4%) 1 (1.5%) 0.579
Exon 3 9 (18%) 15 (23.1%) 0.644
Exon 1 and 2 and 3 AND (Exon 1, 2, 3, and FANCD2) 24 (48%) 25 (38.4%) 0.349
Unknown 1 (2%) 0 (0%)
Total 50 similar mutations 65 similar mutations
Table 3 Major complications of VHL syndrome and extent 
of deletion of the VHL gene
CNSH central nervous system hemangioma, RCH retinal capillary 




of the VHL gene  
(24 matches)
Incomplete deletion 
of the VHL gene  
(26 matches)
CNSH 23 (95.8%) 21 (80.8%)
RCH 4 (16.7%) 5 (19.2%)
RCC 16 (66.7%) 13 (50.0%)
Fig. 1 Frequency of point mutations in the von Hippel–Lindau (VHL) 
gene in an East Asian cohort
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Institute (National Institutes of Health, Bethesda, Mary-
land, USA), 890 patients with clinically definite VHL 
syndrome were screened, among them 335 (37.6%) were 
found to have ocular involvement with RCH [19].
We found that 38.1% (24 of 63) of East Asian VHL kin-
dreds with missense mutations developed RCH, which 
is consistent with the findings of Mettu et  al. [20], who 
found that 38.6% of 412 VHL patients with missense muta-
tions had ocular VHL syndrome. In contrast, the preva-
lence of RCHs was lower in patients with exon deletions 
in the present study. RCHs were present in 12.5% (3 of 24) 
with complete exon deletions and in 19.2% (5 of 26) with 
exon deletions. This is similar to earlier findings that the 
prevalence of RCHs was lower in patients with complete 
deletions [21]. Interestingly, we found that RCHs were iden-
tified less frequently in East Asians; this may be because 
exon deletions are more common in East Asian patients 
with VHL syndrome. However, ascertainment bias in this 
series cannot be excluded since a comprehensive standard 
evaluation of affected individuals was not possible.
RCCs associated with VHL syndrome
The overall frequency of RCC in this cohort was 57.8% 
(89 of 154), which was higher than that reported by Ong 
et  al. [18] and Maher et  al. [4] (35% and 28%, respec-
tively). Previous studies suggested that truncating and 
frameshift mutations confer a higher risk of developing 
RCC compared with missense mutations (75% vs. 57%, 
P = 0.04) [22]. In this study, no significant difference was 
found: 55.6% (10 of 18 families) with nonsense mutations 
developed RCC compared with 63.5% (40 of 63 families) 
with missense mutations (P = 0.541). A smaller propor-
tion of families with frameshift mutations—46.2% (6 
of 13 families)—developed RCC. In this series, nearly 
two-thirds of patients with nonsense or missense muta-
tions were subsequently diagnosed with RCC. For such 
patients, screening for RCC needs to be prioritized.
Strengths and limitations
To minimize publication-related bias, articles in non-
English language journals identified through the litera-
ture review were reviewed by native Chinese or Japanese 
speakers.
However, this study still had several limitations. An 
asymptomatic person can be identified as late as 67 years 
old, and only after careful screening [4]. As such, there may 
be under-estimation of the number of affected individuals, 
as some clinical manifestations may have been missed if 
they were not screened. Another limitation was that East 
Asian VHL patients who did not undergo genetic testing 
and lacked an identified genetic mutation were excluded 
from the analysis. Furthermore, duplicate data could not be 
completely excluded since patient identifiers were removed 
in reports, although we did our best to match identities 
across publications. The other constraint to accurately 
determining genotype-phenotype association was that 
the clinical workup of patients was not always disclosed; 
thus, when a person was not reported to have a particu-
lar manifestation, we could not determine whether this is 
because the investigations returned negative or the patient 
was asymptomatic and not investigated. We acknowledge 
that restricting our study selection to the PubMed database 
is a possible limitation; however, we do not expect bias in 
our conclusions, given the breadth of PubMed and that we 
included non-English language articles in our analysis.
Conclusions
Evidence suggests that the genotypic and phenotypic 
characteristics of East Asian patients with VHL syn-
drome differ from other populations. This should be con-
sidered when making screening recommendations for 
VHL syndrome in Asia.
Patients with VHL syndrome are predisposed to a spec-
trum of benign and malignant tumors. As such, affected 
people should be thoroughly evaluated at regular intervals. 
However, since time and fiscal constraints remain very real 
considerations, physician’s familiarity with the genotypic 
and phenotypic profile of patients with VHL syndrome 
would enable judicious prioritization of screening.
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Table 4 Comparison of frequency of various major compli-
cations of VHL syndrome across different cohorts
CNSH central nervous system hemangioblastoma, RCH retinal capillary 
hemangioblastoma, RCC renal cell carcinoma, PCC pheochromocytoma
Clinical manifes-
tation
Present study Ong et al. [18] Maher et al. [4]




RCH 27.9% (43/154) 73% 59%
RCC 57.8% (89/154) 35% 28%
PCC 14.9% (23/154) 20% 7%
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